Hypothyroidism and Cardiovascular Disease: Role of New Risk Factors and Coagulation Parameters

Hypothyroidism is a common condition and recent epidemiological studies demonstrated that up to 10 percent of subjects may display its subclinical form. Despite the well-known relationship between overt hypothyroidism and cardiovascular disease, few studies demonstrating such a link are available. However, the relationship between hypothyroidism and a variety of cardiovascular risk factors is now well established.

Recent data on new cardiovascular risk factors that were shown to be associated with hypotyroidism are reviewed. Haemostatic and fibrinolytic parameters are disturbed differently according to the stage of hypothyroidism. C-reactive protein levels are higher in patients with overt and subclinical hypotyroidism compared to euthyroid patients. In contrast, elevation of homocysteine values was demonstrated only in overt hypothyroidism. Although no randomized controlled trial evaluated the potential benefits of levothyroxine substitution on the risk to suffer major coronary events in patients with subclinical hypothyroidism, there is growing evidence that this disorder is mainly characterized by a high risk of cardiovascular disease.

Hypothyroidism - subclinical hypothyroidism - atherosclerosis - cardiovascular disease - plasminogen activator inhibitor type 1 - D-dimers - fibrinogen - homocysteine - C-reactive protein

REFERENCES

• 1 Klein I, Ojamaa K. Thyroid hormone and the cardiovascular system.  N Engl J Med. 2001;  344 501-509
• 2 Cappola A R, Ladenson P W. Hypothyroidism and atherosclerosis.  J Clin Endocrinol Metab. 2003;  88 2438-2444
• 3 Perk M, O'Neill B J. The effect of thyroid hormone therapy on angiographic coronary artery disease progression.  Can J Cardiol. 1997;  13 273-276
• 4 Giannattasio C, Rivolta M R, Failla M, Mangoni A A, Stella M L, Mancia G. Large and medium sized artery abnormalities in untreated and treated hypothyroidism.  Eur Heart J. 1997;  18 1492-1498
• 5 Canaris G J, Manowitz N R, Mayor G, Ridgway E C. The Colorado thyroid disease prevalence study.  Arch Intern Med. 2000;  160 526-534
• 6 Taddei S, Caraccio N, Virdis A et al.. Impaired endothelium-dependent vasodilatation in subclinical hypothyroidism: beneficial effect of levothyroxine therapy.  J Clin Endocrinol Metab. 2003;  88 3731-3737
• 7 Nagasaki T, Inaba M, Henmi Y et al.. Change in von Willebrand factor and carotid intima-media thickness in hypothyroid patients with normal thyroid function after levothyroxine replacement therapy.  Eur J Endocrinol. 2004;  150 125-131
• 8 Hak A E, Pols H AP, Visser T J, Drexhage H A, Hofman A, Witteman J CM. Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: The Rotterdam Study.  Ann Intern Med. 2000;  132 270-278
• 9 Willeit J, Kiechl S, Oberhollenzer F et al.. Distinct risk profiles of early and advanced atherosclerosis. Prospective results from the Bruneck study.  Arterioscler Thromb Vasc Biol. 2000;  20 529-537
• 10 Bruckert E, Giral P, Chadarevian R, Turpin G. Low free-thyroxine are a risk factor for subclinical atherosclerosis in euthyroid hyperlipidemic patients.  J Cardiovasc Risk. 1999;  6 327-331
• 11 Auer J, Berent R, Weber T, Lassnig E, Eber B. Thyroid function is associated with presence and severity of coronary atherosclerosis.  Clin Cardiol. 2003;  26 569-573
• 12 Ganotakis E S, Mandalaki K, Tampakaki M et al.. Subclinical hypothyroidism and lipid abnormalities in older women attending a vascular disease prevention clinic: effect of thyroid replacement therapy.  Angiology. 2003;  54 569-576
• 13 Canturk Z, Cetinarslan B, Tarkun I, Canturk N Z, Ozden M. Subclinical hypothyroidism and lipid abnormalities in older women attending a vascular disease prevention clinic: effect of thyroid replacement therapy.  Angiology. 2003;  54 569-576
• 14 Tanis B C, Westendorp G J, Smelt H M. Effect of thyroid substitution on hypercholesterolaemia in patients with subclinical hypothyroidism: a reanalysis of intervention studies.  Clin Endocrinol (Oxf). 1996;  44 643-649
• 15 Danese M D, Ladenson P W, Meinert C L, Powe N R. Clinical review 115: effect of thyroxine therapy on serum lipoproteins in patients with mild thyroid failure: a quantitative review of the literature.  J Clin Endocrinol Metab. 2000;  85 2993-3001
• 16 Oziol L, Faure P, Bertrand N, Chomard P. Inhibition of in vitro macrophage-induced low density lipoprotein oxidation by thyroid compounds.  J Endocrinol. 2003;  177 137-146
• 17 Duntas L H, Mantzou E, Koutras D A. Circulating levels of oxidized low-density lipoprotein in overt and mild hypothyroidism.  Thyroid. 2002;  12 1003-1007
• 18 Muller B, Zulewski H, Huber P, Ratcliffe J G, Staub J J. Impaired action of thyroid hormone associated with smoking in women with hypothyroidism.  N Engl J Med.. 1995;  333 964-969
• 19 Hofbauer L C, Heufelder A E. Coagulation disorders in thyroid diseases.  Eur J Endocrinol. 1997;  136 1-7
• 20 Ford H C, Carter J M. Haemostasis in hypothyroidism.  Postgrad Med J. 1990;  66 280-284
• 21 Farid N R, Griffiths B L, Collins J R, Marshall W H, Ingram D W. Blood coagulation and fibrinolysis in thyroid disease.  Thromb Haemost. 1976;  35 415-422
• 22 Krassas G E, Pontikides N, Kaltsas T et al.. Disturbances of menstruation in hypothyroidism.  Clin Endocrinol (Oxf). 1999;  50 655-659
• 23 Canturk Z, Cetinarslan B, Tarkun I, Canturk N Z, Ozden M, Duman C. Hemostatic system as a risk factor for cardiovascular disease in women with subclinical hypothyroidism.  Thyroid. 2003;  13 971-977
• 24 Erem C, Kavgaci H, Ersoz H O et al.. Blood coagulation and fibrinolytic activity in hypothyroidism.  Int J Clin Pract. 2003;  57 78-81
• 25 Muller B, Tsakiris D A, Roth C B, Guglielmetti M, Staub J J, Marbet G A. Haemostatic profile in hypothyroidism as potential risk factor for vascular or thrombotic disease.  Eur J Clin Invest. 2001;  31 131-137
• 26 Michiels J J, Budde U, van der Planken M, van Vliet H H, Schroyens W, Berneman Z. Acquired von Willebrand syndromes: clinical features, aetiology, pathophysiology, classification and management.  Best Pract Res Clin Haematol.. 2001;  14 401-436
• 27 Levesque H, Borg J Y, Cailleux N et al.. Acquired von Willebrand's syndrome associated with decrease of plasminogen activator and its inhibitor during hypothyroidism.  Eur J Med. 1993;  2 287-288
• 28 Chadarevian R, Bruckert E, Ankri A, Beucler I, Giral P, Turpin G. Relationship between thyroid hormones and plasma D-Dimer levels.  Thromb Haemost. 1998;  79 99-103
• 29 Thornton J G, Parapia L A, Minford A M. Hypothyroidism and Von Willebrand's disease.  Lancet. 1987;  1(8545) 1314-1315
• 30 Myrup B, Bregengard C, Faber J. Primary haemostasis in thyroid disease.  J Intern Med. 1995;  238 59-63
• 31 Erfurth E M, Ericsson U B, Egervall K, Lethagen S R. Effect of acute desmopressin and of long-term thyroxine replacement on haemostasis in hypothyroidism.  Clin Endocrinol (Oxf). 1995;  42 373-378
• 32 Chadarevian R, Bruckert E, Giral P, Turpin G. Relationship between thyroid hormones and fibrinogen levels.  Blood Coagul Fibrinoltsis. 1999;  10 481-486
• 33 Thogersen A M, Jansson J H, Boman K et al.. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor.  Circulation. 1998;  98 2241-2247
• 34 Held C, Hjemdahl, Rehnqvist N et al.. Haemostatic markers, inflammatory parameters and lipids in male and female patients in the Angina Prognosis Study in Stockholm (APSIS). A comparison with healthy controls.  J Intern Med.. 1997;  241 59-69
• 35 Cushman M, Lemaitre R N, Kuller L H et al.. Fibrinolytic activation markers predict myocardial infarction in the elderly. The Cardiovascular Health Study.  Arterioscler Thromb Vasc Biol. 1999;  19 493-498
• 36 Chadarevian R, Bruckert E, Leenhardt L, Giral P, Ankri A, Turpin G. Components of the fibrinolytic system are differently altered in moderate and severe hypothyroidism.  J Clin Endocrinol Metab. 2001;  86 732-737
• 37 Kohno A, Hara Y. Severe myocardial ischemia following hormone replacement in two cases of hypothyroidism with normal coronary arteriogram.  Endocr J. 2001;  48 565-572
• 38 Van Oosterom A T, Kerkhoven P, Veltkamp J J. Metabolism of the coagulation factors of the prothrombin complex in hypothyroidism in man.  Thromb Haemost. 1979;  41 273-285
• 39 Stanger O, Herrmann W, Pietrzik K et al.. DACH-LIGA homocystein (German, Austrian and Swiss homocysteine society): consensus paper on the rational clinical use of homocysteine, folic acid and B-vitamins in cardiovascular and thrombotic diseases: guidelines and recommendations.  Clin Chem Lab Med. 2003;  41 1392-1403
• 40 Christ-Crain M, Meier C, Guglielmetti M et al.. Elevated C-reactive protein and homocysteine values: cardiovascular risk factors in hypothyroidism? A cross-sectional and a double-blind, placebo-controlled trial.  Atherosclerosis. 2003;  166 379-386
• 41 Diekman M J, van der Put N M, Blom H J, Tijssen J G, Wiersinga W M. Determinants of changes in plasma homocysteine in hyperthyroidism and hypothyroidism.  Clin Endocrinol (Oxf). 2001;  54 197-204
• 42 Lien E A, Nedrebo B G, Varhaug J E, Nygard O, Aakvaag A, Ueland P M. Plasma total homocysteine levels during short-term iatrogenic hypothyroidism.  J Clin Endocrinol Metab. 2000;  85 1049-1053
• 43 Ridker P M, Rifai N, Rose L, Buring J E, Cook N R. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events.  N Engl J Med. 2002;  347 1557-1565
• 44 Jublanc C, Bruckert E, Giral P et al.. Relationship of circulating C-reactive protein levels to thyroid status and cardiovascular risk in hyperlipidemic euthyroid subjects: low free thyroxine is associated with elevated hsCRP.  Atherosclerosis. 2004;  172 7-11
• 45 Surks M I, Ortiz E, Daniels G H et al.. Subclinical thyroid disease: scientific review and guidelines for diagnosis and management.  JAMA. 2004;  291 228-238
• 46 Cooper D S. Clinical practice. Subclinical hypothyroidism.  N Engl J Med. 2001;  345 260-265